^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HLA-A*02:01

i
Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
Entrez ID:
Related biomarkers:
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
03/29/2024
Initiation :
11/30/2023
Primary completion :
08/31/2026
Completion :
08/31/2028
HLA-A • CTAG1B
|
HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • fludarabine IV
Phase 1
Neogene Therapeutics, Inc.
Recruiting
Last update posted :
03/26/2024
Initiation :
07/27/2023
Primary completion :
08/01/2026
Completion :
08/01/2039
TP53 • HLA-A
|
TP53 mutation • TP53 R175H • HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • NT-175
Phase 1
Fred Hutchinson Cancer Center
Suspended
Last update posted :
03/21/2024
Initiation :
02/23/2018
Primary completion :
10/16/2027
Completion :
07/16/2028
HLA-A • CD4
|
HLA-A*02:01
|
fludarabine IV • HA-1 T TCR T Cell Immunotherapy
Phase 2
Diwakar Davar
Not yet recruiting
Last update posted :
03/21/2024
Initiation :
06/30/2024
Primary completion :
06/30/2026
Completion :
06/30/2029
LAG3 • CTLA4
|
HLA-A*02:01
|
Kimmtrak (tebentafusp-tebn)
Phase 1/2
Sabine Mueller, MD, PhD
Completed
Last update posted :
02/22/2024
Initiation :
11/18/2016
Primary completion :
12/31/2023
Completion :
12/31/2023
HLA-A
|
HLA-A*02:01 • H3.3K27M • HLA-A*02 • HLA-A2 positive
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC)
Phase 2
Adaptimmune
Recruiting
Last update posted :
02/16/2024
Initiation :
06/26/2023
Primary completion :
10/25/2025
Completion :
10/25/2025
HLA-A • BRCA • PARP1 • MAGEA4
|
HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
|
Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
Phase 1/2
Immunocore Ltd
Completed
Last update posted :
01/24/2024
Initiation :
11/01/2015
Primary completion :
06/19/2023
Completion :
06/19/2023
BRAF • HLA-A
|
BRAF mutation • HLA-A*02:01 • HLA-A*02
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • Kimmtrak (tebentafusp-tebn)
Phase 2
Sun Yat-sen University
Recruiting
Last update posted :
12/27/2023
Initiation :
07/08/2022
Primary completion :
09/01/2024
Completion :
09/01/2024
HLA-A • CTAG1B
|
HLA-A*02:01 • HLA-A*02
|
TAEST16001
Phase 2
GlaxoSmithKline
Active, not recruiting
Last update posted :
10/16/2023
Initiation :
12/31/2019
Primary completion :
10/12/2022
Completion :
07/01/2024
HLA-A • CTAG1B
|
HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
Phase 1/2
Erasmus Medical Center
Recruiting
Last update posted :
09/13/2023
Initiation :
09/29/2021
Primary completion :
07/01/2024
Completion :
07/01/2024
CD8
|
HLA-A*02:01
|
Keytruda (pembrolizumab)
Phase 1/2
University College, London
Recruiting
Last update posted :
08/01/2023
Initiation :
03/25/2022
Primary completion :
05/31/2025
Completion :
05/31/2029
HLA-A
|
HLA-A*02:01 • HLA-A*02
|
Imfinzi (durvalumab) • S-588210
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Completed
Last update posted :
07/19/2023
Initiation :
08/13/2010
Primary completion :
08/01/2020
Completion :
01/06/2023
CTAG1B
|
HLA-A*02:01
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Completed
Last update posted :
01/18/2023
Initiation :
08/04/2010
Primary completion :
12/12/2016
Completion :
12/12/2016
CTAG1B
|
HLA-A*02:01
|
Opdivo (nivolumab)
Phase 1
GlaxoSmithKline
Active, not recruiting
Last update posted :
12/29/2022
Initiation :
12/21/2020
Primary completion :
12/04/2025
Completion :
12/04/2025
PD-L1 • BRAF • ALK • ROS1 • HLA-A • CTAG1B • CTAG2
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132 • cyclophosphamide intravenous
Phase 1/2
University Hospital, Geneva
Active, not recruiting
Last update posted :
12/26/2022
Initiation :
10/25/2018
Primary completion :
12/31/2023
Completion :
12/31/2023
PD-L1
|
HLA-A*02:01
|
Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950
Phase 2
GlaxoSmithKline
Active, not recruiting
Last update posted :
10/31/2022
Initiation :
12/31/2019
Primary completion :
11/30/2022
Completion :
07/31/2026
HLA-A • CTAG1B
|
HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
Phase 1
Athenex, Inc.
Withdrawn
Last update posted :
09/02/2022
Initiation :
08/11/2021
Primary completion :
10/01/2022
Completion :
12/01/2024
CD8 • CTAG1B
|
HLA-A*02:01 • CTAG1B expression
|
TCRT-ESO-A2
Phase 1
Medigene AG
Withdrawn
Last update posted :
10/08/2021
Initiation :
07/02/2020
Primary completion :
07/01/2023
Completion :
07/01/2025
CD8 • HLA-A
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
08/13/2021
Initiation :
05/20/2010
Primary completion :
07/20/2020
Completion :
07/20/2020
CD8 • CD4
|
HLA-A*02:01
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
02/04/2021
Initiation :
09/01/2019
Primary completion :
05/01/2021
Completion :
12/01/2021
HLA-A • MSLN • CTAG1B
|
HLA-A*02:01 • MSLN positive • HLA-A positive
|
cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Phase 1
Jonsson Comprehensive Cancer Center
Completed
Last update posted :
08/03/2020
Initiation :
04/01/2004
Primary completion :
07/01/2008
Completion :
10/01/2009
HLA-A • CTLA4
|
HLA-A*02:01 • HLA-A positive
|
Imjudo (tremelimumab)
Phase 1/2
Jonsson Comprehensive Cancer Center
Completed
Last update posted :
08/03/2020
Initiation :
01/01/2001
Primary completion :
12/01/2004
Completion :
10/01/2008
AFP
|
HLA-A*02:01
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
12/11/2019
Initiation :
03/01/2018
Primary completion :
03/01/2023
Completion :
03/01/2023
MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
|
HLA-A*02:01 • CD19 expression • HLA-A positive
|
cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Phase 1/2
Cell Medica Ltd
Completed
Last update posted :
10/02/2018
Initiation :
09/01/2015
Primary completion :
05/01/2018
Completion :
05/01/2018
WT1
|
HLA-A*02:01
|
CMD-602
Phase 2
University Hospital Southampton NHS Foundation ...
Completed
Last update posted :
09/07/2018
Initiation :
02/01/2011
Primary completion :
02/01/2013
Completion :
02/26/2013
ABL1 • BCR • WT1
|
HLA-A*02:01
|
p.DOM-WT1-126 DNA vaccine
Phase 1
National Heart, Lung, and Blood Institute (NHLBI)
Completed
Last update posted :
07/02/2017
Initiation :
12/22/2005
Primary completion :
10/26/2007
Completion :
10/26/2007
CSF2
|
HLA-A*02:01
Phase 1/2
Fred Hutchinson Cancer Center
Completed
Last update posted :
02/15/2017
Initiation :
04/01/2012
Primary completion :
04/01/2014
Completion :
07/01/2014
CD19 • HLA-B
|
HLA-A*02:01 • CD19 expression
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
10/28/2015
Initiation :
12/01/2008
Primary completion :
08/01/2011
Completion :
08/01/2011
IL2
|
HLA-A*02:01
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous